Drug Profile
Research programme: cancer therapeutics - Le Sun Pharmaceuticals
Alternative Names: LS-008; LS-078; LSF-202; LSF-206Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Le Sun Pharmaceuticals
- Developer Le Sun Pharmaceuticals; Yabao Pharmaceutical Group
- Class Antineoplastics; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Cyclin dependent kinase 9 inhibitors; Maturation-promoting factor inhibitors; Polo-like kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in China (PO)
- 01 Jan 2014 Preclinical trials in Cancer in China (PO)